ISCT Leads Publication of Patient Advisory on Stem Cell Therapy and Medical Tourism
Tuesday, September 10, 2013
Posted by: ISCT
ISCT is pleased to announce the publication of the Patient Advisory for Stem Cell Therapy and Medical Tourism. This unified statement was crafted by professional societies dedicated to advancing cell and gene therapy who also feel it necessary to share important information with patients and families contemplating cell therapy or experimental stem cell procedures. The statement is intended to outline best practices to assist patients and family members in their healthcare decisions.
The Cell Therapy Liaison Meeting (CTLM) Stakeholder Group, a group formed between ISCT and 23 other leading cell and gene therapy organizations held its latest annual meeting with the FDA on November 19, 2012 in Bethesda, Maryland, USA. Following the presentation from Dr. Kurt Gunter, ISCT President, entitled "Cell Therapy Medical Tourism”, he, along with the ISCT North America Legal & Regulatory Affairs Committee Co-Chairs Karen Nichols, Esq. and Dr. William Janssen, drafted the Patient Advisory Statement. With further input and collaboration from members of the CTLM Stakeholder Group, the statement has now been finalized and is publicly available.
For further reference on this subject matter, please refer to the ISCT White Paper entitled "Cell therapy medical tourism: Time for action” that was published through the Society’s official journal Cytotherapy. Cytotherapy, 2010; 12: 965–968.
For further details, please contact Head Office (email@example.com).